Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episo
Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available
10.1212/wnl.90.15_supplement.s20.001